News and Announcements
Imagion Biosystems announces positive results of its clinical trial data
- Published February 16, 2023 6:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imagion Biosystems (ASX: IBX) released this week the results of an independent review of their clinical trial data, which confirms that the company’s targeted imaging agent is safe and detectable by MRI machines. The company also announced it has dosed 9 patients in its Phase 1 HER2 breast cancer study still open for enrollment in four sites across Australia.
Guided by the clinical results, Imagion has decided to prioritize the development of its targeted nanoparticles in conjuncture with the existing MRI technology, as opposed to IBX’s proprietary MRX machines. With this shift in strategy, the company hopes to eliminate the near-term expense and risks associated with developing and introducing a new type of detection technology.
The company held a webinar yesterday to discuss the announcement with shareholders. The recording can be viewed here.
Sharing the full announcement with you to see if we can get an inclusion in WI’s next newsletter. It would be great to include the link to the recording in the company blurb to drive traffic to the site.
Connect with the company and learn more about Imagion Biosystems by accessing their deal room here.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
